Given the documented evidence of DUSP enzymes having pro‐oncogenic activities in various cancers [37, 38], we have investigated the therapeutic potential of BCI, a dual DUSP1/6 inhibitor, across a range of NB cell lines. This evidence concerns the gene DUSP1 and neuroblastoma.